Bioassay protocol metadata annotation: Proposed standards adoption
- PMID: 39427714
- DOI: 10.1016/j.slasd.2024.100188
Bioassay protocol metadata annotation: Proposed standards adoption
Abstract
We present a standardized metadata template for assays used in pharmaceutical drug discovery research, according to the FAIR principles. We also describe the use of an automated tool for annotating assays from a variety of sources, including PubChem, commercial assay providers, and the peer-reviewed literature, to this metadata template. Adoption of a standardized metadata template will allow drug discovery scientists to better understand and compare the increasing amounts of assay data becoming available, and will facilitate the use of artificial intelligence tools and other computational methods for analysis and prediction. Since bioassays drive advances in biomedical research, improvements in assay metadata can improve productivity in discovery of new therapeutics, platform technologies, and assay methods.
Keywords: Assay registration; Bioassay; Data standards; Drug discovery; FAIR; Metadata; Ontology; Protocol.
Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Vladimir A. Makarov reports financial support was provided by F Hoffmann-La Roche Ltd. Vladimir A. Makarov reports financial support was provided by Novartis Pharmaceuticals Corporation. Vladimir A. Makarov reports financial support was provided by GlaxoSmithKline Inc. Vladimir A. Makarov reports financial support was provided by Bristol Myers Squibb Co. Vladimir A. Makarov reports financial support was provided by AbbVie Inc. Vladimir A. Makarov reports financial support was provided by AstraZeneca Pharmaceuticals LP. Isabella Feierberg reports a relationship with Collaborative Drug Discovery Inc that includes: board membership. Isabella Feierberg reports a relationship with AstraZeneca Pharmaceuticals LP that includes: equity or stocks. Samantha Jeschonek reports a relationship with Revvity Inc that includes: equity or stocks. Vladimir A. Makarov reports a relationship with Elucidata Corporation that includes: consulting or advisory. Vladimir A. Makarov reports a relationship with Zifo RnD Solutions that includes: consulting or advisory. Vladimir A. Makarov reports a relationship with IBIS Inc. that includes: consulting or advisory. Vladimir A. Makarov reports a relationship with California State University Channel Islands that includes: employment. Ellen Berg reports a relationship with Phenovista that includes: board membership. Ellen Berg reports a relationship with Cashel Neural that includes: board membership. Ellen Berg reports a relationship with National Institutes of Health that includes: board membership. Ellen Berg reports a relationship with University of California San Francisco that includes: consulting or advisory. Vladimir A. Makarov reports a relationship with PIPA LLC that includes: consulting or advisory. Vladimir A. Makarov reports a relationship with Exelixis Inc that includes: consulting or advisory. Alex Clark has patent #US20160026622A1 issued to Collaborative Drug Discovery. Isabella Feierberg, co-author, previously employed by AstraZeneca; Ellen Berg, co-author, previously employed by Eurofins Panlabs; Sheryl Denker, co-author, previously employed by Eurofins Panlabs; Dana Vanderwall, co-author, previously employed by BMS; Samantha Jeschonek, co-author, previously employed by Collaborative Drug Discovery Inc. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
